Abbott Laboratories에 대한 매도 수량은 투자자에게 Abbott Laboratories의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Abbott Laboratories (NYSE:ABT) 주식, 공매도 수량 보고

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

News

Pre-Market Outlook

Markets

Trading Ideas

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 개선된 것으로 나타냈지만, 화요일(21일)에도 여전히 &#39;공포&#39; 영역에 머물렀다.화요일 미국 증시는 도널드 트럼프가 1월 20일 제47대 미국 대통령으로 취임한 이후 투자자들이 국내 친화적인 정책에 베팅하면서 다우존스 지수가 장중 500포인트 이상 상승하는 등 상승세로 마감했다. 

트럼프 취임 후 다우 지수 500p 상승: 투자 심리 개선, 탐욕 지수는 여전히 &#39;공포&#39; 영역

Earnings

IBKR

NFLX

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보이고 있는 가운데, 오늘 투자자들의 주목을 받을 만한 주식들은 다음과 같다: 애벗 래버러토리(NYSE:ABT)는 분기 실적을 개장 전 발표할 예정으로, 월스트리트에서 분기 이익이 주당 1.34달러, 매출이 110억 1천만 달러에 이를 것으로 예상하고 있다. 애벗의 주식은 애프터 마켓에서 0.08% 상승하여 116.88달러에 거래되고 있다.

수요일 주목해야 할 주식: 애벗 랩, 넷플릭스, P&amp;G, 인터랙티브 브로커스 및 존슨앤드존슨

General

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.

콜럼버스 데이: 오늘 주식시장이 열리나요?

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Abbott Laboratories shares are trading lower after the company missed Q4 revenue estimates.

Guidance

Health Care

Abbott Laboratories Expects 2025 Adjusted EPS Of $5.05-$5.25 Versus Consensus Of $5.16, Abbott Expects 2025 Organic Sales Growth Of 7.5%-8.5% With Adjusted Operating Margin Of 23.5%-24.0%

Abbott Laboratories Expects Q1 2025 Adjusted EPS Of $1.05-$1.09 Versus Consensus Of $1.11

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported quarterly earnings of $1.34 per share which met the analyst consensus estimate. This is a 12.61 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $10.97 billion which missed the analyst consensus estimate of $11.01 billion by 0.35 percent. This is a 7.16 percent increase over sales of $10.24 billion the same period last year.

Abbott Laboratories Q4 2024 Adj. EPS $1.34, Inline, Sales $10.97B Miss $11.01B Estimate

U.S. stocks could open on a positive note on Wednesday, continuing to rally after <a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now">Donald Trump's inauguration</a> as the 47th President of the U.S. on Monday. Futures point to a second consecutive day of positive start to the Trump presidency.
As the new administration settles in, President Trump announced an ambitious $500 billion artificial intelligence project dubbed Stargate. This venture includes Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI, and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>).
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.84%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.17%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.17%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 0.37% to $605.24 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.77% to $528.86, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Tuesday on a positive note, with Dow Jones and S&amp;P 500 ending the day with major gains, while the Nasdaq closed 0.64% in the green.
Crude oil prices edged lower as traders await clarity about the new Trump administration's agenda.
Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) were among the top gainers on Tuesday, surging 8.48% and 7.17% during the session respectively.
On the economic data front, U.S. industrial production rose by 0.9% in December, ahead of estimates of a 0.3% increase. Housing starts rose by 15.8% from the previous month to an annualized rate of 1.499 million units in December.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, real estate, and healthcare stocks recording gains on Tuesday.
However, energy stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.64%</td>
<td>19,756.78</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.88%</td>
<td>6,049.24</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.24%</td>
<td>44,025.81</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.85%</td>
<td>2,317.97</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, chief market strategist at Carson Global, underscored that there is a high possibility that 2025 could be a good year as far as equity markets are concerned.
"The year after an election year has been quite strong lately, with stocks higher 9 of the past 10 times going back to Reagan&#8217;s second term," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The year after an election year has been quite strong lately, with stocks higher 9 of the past 10 times going back to Reagan&#39;s second term. <a href="https://t.co/Nkx8DDehQ8">pic.twitter.com/Nkx8DDehQ8</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1881724906460868653?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In 2017, the first year of Trump's previous term, the Dow and S&amp;P 500 delivered a return of 19.4%. Likewise, in Biden's first year in office, the return stood at 26.9%.
Jeremy Siegel, Wharton professor and senior economist at WisdomTree, underscored the resilient U.S. economy and positive indicators going into 2025.
"The outlook for Q4 GDP growth is strong, with estimates ranging between 2.5% and 3%, a testament to the underlying strength of the economy as we transition into 2025," he said.
He also has a word of caution about the impact of Trump's tariff plans, but noted that they are "likely months away."
"The S&amp;P 500 thus far remains resilient, but I maintain my call for a correction this year as bond yields rise further, which could pressure valuations. This presents opportunities for less richly priced stocks, sectors, and strategies."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Here's what investors will keep an eye on for Wednesday and the rest of the week:
<ul>
<li>On Wednesday, leading economic indicator data will be released at 10:00 a.m., ET.</li>
<li>On Thursday, initial jobless claims data will be released at 8:30 a.m. ET.</li>
<li>On Friday, S&amp;P flash services PMI and manufacturing PMI will be released at 9:45 a.m. ET.</li>
<li>Existing home sales and consumer sentiment data will be released at 10 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) stock gained over 8% in premarket trade on Wednesday after President Trump announced the Stargate AI joint venture, comprising Oracle, OpenAI, and SoftBank.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) surged over 14% after stunning the Street with 20 million new subscribers and a price hike amid its best quarterly performance ever.</li>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) and other chip stocks gained in pre-market after Trump's AI announcement.</li>
<li>Investors are awaiting earnings results from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures fell in the early New York session, declining by 0.42% to hover around $75.51 per barrel.
The 10-year Treasury note yield edged higher to 4.585%.
Most of the major Asian markets were mixed on Wednesday, while European markets were in the green in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43118541/bitcoin-ethereum-dogecoin-rally-amid-secs-plans-to-establish-crypto-regulations-top-trader-issues-bold-3000-target-for-btc-this-cycle">Bitcoin, Ethereum Rally Amid SEC&#8217;s Plans To Establish Crypto Regulations: Top Trader Issues $300,000 Target For BTC This Cycle</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Futures

Economics

Federal Reserve

MSFT

NVDA

ORCL

SFTBY

US Stocks Likely To Open Higher As Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch

<h3>Companies Reporting Before The Bell</h3>
• HDFC Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $422.93 billion. 
• Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) is likely to report quarterly earnings at $6.61 per share on revenue of $10.80 billion. 
• Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) is projected to report quarterly earnings at $1.86 per share on revenue of $21.59 billion. 
• Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) is projected to report quarterly earnings at $1.26 per share on revenue of $837.57 million. 
• GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) is expected to report quarterly earnings at $2.37 per share on revenue of $10.70 billion. 
• Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $22.45 billion. 
• Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) is likely to report quarterly earnings at $1.28 per share on revenue of $3.27 billion. 
• Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) is projected to report quarterly earnings at $5.23 per share on revenue of $1.45 billion. 
• TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) is projected to report quarterly earnings at $1.89 per share on revenue of $3.91 billion. 
• OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $176.15 million. 
• F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $408.00 million. 
• LG Display Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $5.87 billion. 
• HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) is likely to report quarterly earnings at $0.58 per share on revenue of $57.48 million. 
• Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $5.63 billion. 
• BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $261.25 million. 
• United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) is likely to report earnings for its fourth quarter. 
• Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) is projected to report quarterly earnings at $1.34 per share on revenue of $11.04 billion. 
• Commerce Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBSH#NASDAQ">CBSH</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $417.18 million. 
• Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is expected to report quarterly earnings at $0.64 per share on revenue of $2.01 billion. 
• Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $4.06 billion. 
<h3>Companies Reporting After The Bell</h3>
• Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) is likely to report quarterly earnings at $0.25 per share on revenue of $108.44 million. 
• Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) is projected to report quarterly earnings at $1.63 per share on revenue of $3.98 billion. 
• Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $87.75 million. 
• Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $59.62 million. 
• Wesbanco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $156.42 million. 
• First Internet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBK#NASDAQ">INBK</a>) is expected to report quarterly earnings at $0.91 per share on revenue of $24.88 million. 
• NVE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEC#NASDAQ">NVEC</a>) is estimated to report earnings for its third quarter. 
• Univest Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UVSP#NASDAQ">UVSP</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $73.45 million. 
• SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) is likely to report quarterly earnings at $1.53 per share on revenue of $156.30 million. 
• Cohen &amp; Steers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNS#NYSE">CNS</a>) is projected to report quarterly earnings at $0.81 per share on revenue of $140.72 million. 
• Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $4.13 billion. 
• Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $1.88 billion. 
• Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $55.96 million. 
• RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) is expected to report quarterly earnings at $1.04 per share on revenue of $435.02 million. 
• CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) is expected to report quarterly earnings at $5.23 per share on revenue of $2.02 billion. 
• Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $74.67 million. 
• Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $480.50 million. 
• National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) is likely to report quarterly earnings at $0.79 per share on revenue of $107.38 million. 
• QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) is projected to report quarterly earnings at $1.73 per share on revenue of $96.56 million. 
• Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is projected to report quarterly earnings at $1.09 per share on revenue of $185.11 million. 
• Bankwell Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWFG#NASDAQ">BWFG</a>) is projected to report quarterly earnings at $0.65 per share on revenue of $22.12 million. 
• Third Coast Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $41.96 million. 
• Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) is projected to report quarterly earnings at $1.55 per share on revenue of $980.53 million. 
• Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $131.10 million. 
• Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $100.68 million. 
• Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $62.78 million. 
• Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $457.77 million. 
• Colony Bankcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NYSE">CBAN</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $28.90 million. 
• Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) is estimated to report quarterly earnings at $1.21 per share on revenue of $156.09 million. 
• Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $3.29 billion. 
• Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) is estimated to report quarterly earnings at $3.26 per share on revenue of $4.39 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

AMTB

BANR

BWFG

CACI

CADE

CATY

CBAN

CBSH

EGBN

EQBK

HBNC

INBK

NBHC

NVEC

OSBC

PLXS

QCRH

STLD

TCBX

TFIN

UVSP

WSBC

Earnings Scheduled For January 22, 2025

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Tuesday, with the Dow Jones index gaining more than 500 points during the session as investors bet on more domestic-friendly policies following Donald Trump&#8217;s inauguration on Jan. 20 as the 47th U.S. President.
All three major indices also recorded their first weekly gain of 2025. The Dow jumped 3.7%, while the S&amp;P 500 added 2.9% last week. The Nasdaq, meanwhile, surged 2.5% during the week to notch its strongest weekly performance since December.
D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported better-than-expected first-quarter results. 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported upbeat fourth-quarter 2024 results and initiated 2025 guidance.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, real estate, and health care stocks recording gains on Tuesday. However, energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 538 points to 44,025.81 on Tuesday. The S&amp;P 500 rose 0.88% to 6,049.24, while the Nasdaq Composite climbed 0.64% at 19,756.78 during Tuesday's session.
Investors are awaiting earnings results from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 40.8, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 37.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock"> Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to report quarterly earnings at $1.34 per share on revenue of $11.01 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Abbott shares went up 0.08% to $116.88 in after-hours trading.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected fourth-quarter financial results. Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company&#8217;s previous range. Netflix shares jumped 14.4% to $994.80 in the after-hours trading session.</li>
<li>Analysts are expecting Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.86 per share on revenue of $21.54 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 1% to $163.38 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) posted better-than-expected fourth-quarter financial results. The company reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $1.39 billion which beat the analyst consensus estimate of $1.37 billion. Interactive Brokers shares gained 3.5% to $199.59 in the after-hours trading session.</li>
<li>Analysts expect Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) to post quarterly earnings at $2.01 per share on revenue of $22.44 billion before the opening bell. Johnson &amp; Johnson shares gained 0.6% to $149.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and maintains $135 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $135 Price Target

The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027. 
The dye, found in products ranging from candy to cold medicine, has been scrutinized for decades. This move follows the FDA's 1990 prohibition of the dye in cosmetics due to its carcinogenic <a href="https://www.benzinga.com/fda-calendar">effects on lab rats</a>.
The decision, announced on Wednesday, comes in response to a 2022 petition by consumer advocacy groups, including Consumer Reports, Public Citizen and the Environmental Working Group, urging the FDA to eliminate Red No. 3 from the American diet. The agency acknowledged the dye induces cancer in male rats and is subject to the Delaney Clause, a regulation banning substances shown to cause cancer in humans or animals from being used in food.
"Red Dye 3 poses an unacceptable risk to our health, especially when safer alternatives are readily available," said Brian Ronholm, director of food policy at Consumer Reports, <a href="https://www.bloomberg.com/news/articles/2025-01-15/us-fda-to-ban-red-dye-no-3-rfk-went-after-due-to-cancer-link?srnd=homepage-americas&amp;sref=TBDibEcD">as reported</a> by Bloomberg. Advocacy groups have argued that banning the dye will encourage manufacturers to adopt safer ingredients already in use in Europe and other countries.
<h1 class="wp-block-heading">Children's Products Loaded With Red Dye No. 3</h1>
The dye, widely prevalent in U.S. supermarkets, seems to be especially used to color food items consumed by young children. An analysis by the healthy food app <a href="https://www.gococo.app/">GoCoCo</a> revealed its presence in 26% of baking decorations, 16% of chewing gum, 13% of candy and 11% of cookies. 
Products such as Brach's candy corn produced by the Ferrara Candy Co., Betty Crocker sprinkles made by General Mills Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) and strawberry Ensure from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) contain Red dye No 3. It is also used in medications, including Takeda Pharmaceutical Co. Ltd.&#8217;s (NYSE: TAK) Vyvanse, a medication used to treat attention deficit hyperactivity disorder, which <a href="https://www.cdc.gov/adhd/data/index.html#:~:text=Millions%20of%20U.S.%20children%20have%20been%20diagnosed%20with%20ADHD.&amp;text=An%20estimated%207%20million%20(11.4,parents%20using%20data%20from%202022.">affects</a> seven million U.S. children and teens.&nbsp;Store-brand heartburn remedies from Costco Wholesale Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) and Rite Aid also contain Red dye No 3.
"If you can't put it on your skin why would you eat it?" said Linda Birnbaum, former director of the National Institute of Environmental Health Sciences and the National Toxicology Program, in an interview with Bloomberg last month. "Bright red dye is completely unessential. We don't need bright red candies."
The industry expressed support for the FDA's regulatory authority. "Our consumers and everyone in the food industry want and expect a strong FDA," the National Confectioners Association said in a statement.
Ferrara and General Mills have indicated their readiness to meet the new standards. Ferrara has already begun reformulating products.
While the ban marks progress, advocates like Scott Faber of the Environmental Working Group are urging the FDA to tackle other dyes, including Red No. 40 and Yellow Nos. 5 and 6, linked to hyperactivity and other health concerns.
Now Read: • <a href="https://www.benzinga.com/government/regulations/24/11/42144709/kennedys-war-on-food-dyes-could-be-coming-to-your-breakfast-table">Kennedy's War On Food Dyes Could Be Coming To Your Breakfast Table</a>
Photo: Shutterstock.

Government

Regulations

COST

FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$25.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>3.5K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$115.00</td>
<td>$64.3K</td>
<td>26</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$26.00</td>
<td>$48.1K</td>
<td>12.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ONC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$40.5K</td>
<td>0</td>
<td>406</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$75.0K</td>
<td>39</td>
<td>302</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$175.00</td>
<td>$90.1K</td>
<td>7.2K</td>
<td>170</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$40.7K</td>
<td>203</td>
<td>167</td>
</tr>
<tr>
<td>OPCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$37.6K</td>
<td>208</td>
<td>157</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$55.3K</td>
<td>421</td>
<td>154</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$30.6K</td>
<td>556</td>
<td>139</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with neutral sentiment. It expires in 66 day(s) on March 21, 2025. Parties traded 1000 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $380.0K, with a price of $380.0 per contract. There were 2393 open contracts at this strike prior to today, and today 3522 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bullish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 99 contract(s) at a $115.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $64.3K, with a price of $645.0 per contract. There were 26 open contracts at this strike prior to today, and today 3057 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 501 contract(s) at a $26.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $96.0 per contract. There were 12780 open contracts at this strike prior to today, and today 1248 contract(s) were bought and sold. 
• Regarding ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 33 contract(s) at a $180.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $1230.0 per contract. There were 0 open contracts at this strike prior to today, and today 406 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $145.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $75.0K, with a price of $750.0 per contract. There were 39 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 142 contract(s) at a $175.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $90.1K, with a price of $635.0 per contract. There were 7210 open contracts at this strike prior to today, and today 170 contract(s) were bought and sold. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 167 contract(s) at a $35.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $40.7K, with a price of $245.0 per contract. There were 203 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
• Regarding OPCH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 47 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $801.0 per contract. There were 208 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a put option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 82 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $55.3K, with a price of $679.0 per contract. There were 421 open contracts at this strike prior to today, and today 154 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bearish, expiring in 3 day(s) on January 17, 2025. This event was a transfer of 42 contract(s) at a $580.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $730.0 per contract. There were 556 open contracts at this strike prior to today, and today 139 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

BIIB

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

OPCH

PRAX

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

GEHC

SOLV

VEEV

8 Health Care Stocks Whale Activity In Today's Session

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with a <a href="https://www.benzinga.com/quote/AVR/analyst-ratings" target="_blank" rel="noreferrer noopener">Positive rating and a forecast of $22</a>.
The analyst notes that Anteris Technologies&#8217; DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028
Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.
Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression" rel="noreferrer noopener">Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees &#8216;Opportunity To Restore Free Expression&#8217;</a>
The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.
Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.
In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.
Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company&#8217;s proprietary ADAPT tissue technology, Miksic writes.
For FY25, the analyst estimates the company to report a loss of $(1.30) per share.
Price Action: AVR shares are trading higher by 2.67% to $5.760&nbsp;at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/25/01/42830046/amd-reveals-new-ai-processors-gaming-products-ahead-of-ces-2025-shares-rise" target="_blank" rel="noreferrer noopener">AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025</a></li>
</ul>
Anteris logo courtesy of company

Movers

Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735587015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Abbott Laboratories?

<a href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" title="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom">https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom</a>

Biotech

DXCM

Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments

Alberta Government Adds Abbott Laboratories' Freestyle Libre 2 Flash Glucose Monitoring System To Alberta Drug Benefit List

Abbott Reports Completion Of In-human Leadless Left Bundle Branch Area Pacing  Procedures Using Investigational AVEIR CSP Leadless Pacemaker System

<ul>
<li>Dividend increased by 7.3%</li>
<li>Quarterly dividend payout has increased more than 60% since 2020</li>
<li>404th consecutive quarterly dividend to be paid by Abbott since 1924</li>
</ul>
ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend&nbsp;payout has increased more than 60% since 2020.

Dividends

Abbott Increases Quarterly Dividend From $0.55 To $0.59 Per Share

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is one of his <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">&#8220;least favorite oils.&#8221;</a>
On Monday, UBS analyst Josh Silverstein maintained Occidental Petroleum with a Neutral and lowered the price target from&nbsp;$58&nbsp;to&nbsp;$51, while Wells Fargo analyst Roger Read maintained the stock with an Equal-Weight and cut the price target from&nbsp;$56&nbsp;to&nbsp;$53.
&#8220;I think it's a very good situation,&#8221; Cramer said when asked about The Cooper Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>).
<ul>
<li><a href="https://analytics.google.com/analytics/web/#/p283071105/reports/explorer?params=_u..nav%3Dmaui%26_r..dataFilters%3D%5B%7B%22type%22:1,%22fieldName%22:%22landingPage%22,%22evaluationType%22:4,%22expressionList%22:%5B%22%252Ftrading-ideas%252Flong-ideas%252F24%252F04%252F38312296%252Fjim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro%22%5D,%22complement%22:false,%22isCaseSensitive%22:true,%22expression%22:%22%22%7D%5D&amp;r=6342961161&amp;ruid=all-pages-and-screens,life-cycle,engagement&amp;collectionId=6114769606" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38312296/jim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro">Jim Cramer Recommends Buying Ethereum Or Bitcoin Instead Of This Stock: &#8216;Let&#8217;s Not Fool Around</a>
Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is the &#8220;ultimate speculative, and as long as you know that, then I'm absolutely fine with it,&#8221; Cramer said.
Cramer recommended to keep owning Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and also recommended buying more in case it goes down.
The Mad Money host said he likes Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>). &#8220;I think that their legal stuff is really largely behind them,&#8221; he added.
When asked about Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), he said, &#8220;It's a good situation.&#8221;
As for Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>), the company &#8220;missed the numbers by a mile,&#8221; Cramer said. &#8220;And when I see that, that often means that the next numbers' going to be missed too. So let's be careful there.&#8221;
Price Action:
<ul>
<li>Occidental Petroleum shares fell 0.9% to settle at $48.05 on Tuesday.</li>
<li>Cooper Companies shares fell 0.2% to close at $99.08.</li>
<li>Energy Transfer shares slipped 0.5% to settle at $18.74 on Tuesday.</li>
<li>Abbott shares gained 0.5% to $115.50 on Tuesday.</li>
<li>Kinder Morgan shares fell 0.8% to close at $26.89 on Tuesday.</li>
<li>Advanced Drainage Systems shares fell 1.7% to settle at $128.24 during the session.</li>
<li>Archer Aviation shares slipped 1.3% to close at $7.72 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ACHR

Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 14.63% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 0.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733495423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Abbott Laboratories's Recent Short Interest

Abbott Laboratories Non-GAAP EPS of $1.34 in-line, revenue of $11B misses by $30M

Which reflects an increase of 150 basis points at the midpoint compared to 2024. Published first on TheFly – the ultimate source for real-time, mar...

Abbott sees FY25 adjusted operating margin 23.5%-24.0% of sales

Reports Q4 revenue $11B, consensus $11.03B. "We finished the year with very strong momentum. Sales growth and earnings per share growth in the four...

Abbott reports Q4 adjusted EPS $1.34, consensus $1.34

Abbott (ABT) projects full-year 2025 organic sales growth to be in the range of 7.5%-8.5%. FY25 revenue consensus $44.97B. Published first on TheFl...

Abbott sees FY25 adjusted EPS $5.05-$5.25, consensus $5.16

07:03 EST Abbott (ABT) sees Q1 adjusted EPS $1.05-$1.09, consensus $1.12 Published first on TheFly – the ultimate source for real-time, market-movi...

Abbott sees Q1 adjusted EPS $1.05-$1.09, consensus $1.12

Today, several major companies are expected to report earnings: Abbott Laboratories (ABT), Alcoa (AA), Discover Financial Services (DFS), Halliburt...

Options Volatility and Implied Earnings Moves Today, January 22, 2025

Earnings Snapshot: Abbott Laboratories Q4 misses revenue estimates; initiates Q1 and FY25 outlook

Abbott in charts: Medical Devices sales reach all-time high in Q4

Abbott Laboratories slips after Q4 topline miss

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – Netflix (NFLX) up 15% Ally Financial (ALLY) u...

Morning Movers: Netflix shares rise following subscriber blowout

Screenshot 2024-12-03 at 7.43.04 PM

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott

Abbott Increases Quarterly Dividend for 53rd Consecutive Year

Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart

Abbott's FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta

Abbott Hosts Conference Call for Fourth-Quarter Earnings

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

PUBLIC HEALTH ADVOCACY INSTITUTE (PHAI) FILES CLASS ACTION AGAINST ABBOTT LABORATORIES OVER MARKETING OF "TODDLER MILK"

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

Comments

Abbott Laboratories

매도 수량

Abbott Laboratories (NYSE:ABT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌